Garland Greg C. 4
4 · AMGEN INC · Filed May 21, 2026
Research Summary
AI-generated summary of this filing
Amgen (AMGN) Director Greg C. Garland Receives RSU Award
What Happened Greg C. Garland, a director of Amgen Inc. (AMGN), received an award of 665 restricted stock units (RSUs) on May 19, 2026. The filing reports the acquisition price as $0.00 because these were RSUs that vested immediately and will be paid out one-for-one in Amgen common shares. This is a grant/compensation event (transaction code A), not an open-market purchase or sale.
Key Details
- Transaction date: 2026-05-19; Form 4 filed: 2026-05-21 (timely filing).
- Transaction type: Award/Grant (code A); 665 RSUs acquired at reported $0.00.
- Shares owned after transaction: Not specified in the provided filing.
- Footnote: RSUs were granted under Amgen’s 2009 Director Incentive Program and vested immediately; vested RSUs are paid one-to-one in common stock and may be deferred per an elected schedule.
- No indication of a 10b5-1 plan, tax-withholding sale, or late filing in this report.
Context RSU grants to directors are routine compensation and do not, by themselves, signal insider buying or selling sentiment. Because these RSUs vested immediately and will convert to shares, the director will receive common stock unless he elects to defer payout per the plan rules.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-19+665→ 13,848 total
Footnotes (1)
- [F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.